Evaxion Biotech (EVAX) has released an update.
Evaxion Biotech has reported promising results from its phase 2 trial of EVX-01, an AI-designed personalized cancer vaccine, showing a 69% Overall Response Rate and tumor reduction in 15 out of 16 melanoma patients. The vaccine, leveraging the company’s AI-Immunology platform, demonstrated high immunogenicity and significant potential for commercialization in the growing melanoma treatment market. A webinar discussing the data will be held with Professor Georgina V. Long, highlighting the treatment’s transformative prospects for advanced melanoma.
For further insights into EVAX stock, check out TipRanks’ Stock Analysis page.
